{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-014063","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.438768+00:00","generated_at":"2026-06-25T17:55:54.266967+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ChromaDex Q1 net sales $17.3M (+18% YoY); net loss $7.7M; adj EBITDA loss narrows","bullets":["Net sales $17.3M (+18% YoY); Tru Niagen sales $14.9M (+20% from Q1 2021).","Gross margin 61.0% (down from 62.9%); net loss $7.7M ($0.11 per share) vs $7.4M ($0.12) last year.","Adjusted EBITDA loss (incl legal) $4.5M, a $1.2M improvement from Q1 2021.","Launched Tru Niagen Immune in April 2022; new TV campaign with encouraging early results.","Granted U.S. continuation patent covering NR chloride, malate, and tartrate salts through 2037."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-014063","json":"https://secwatch.observer/filing/0001628280-22-014063.json","markdown":"https://secwatch.observer/filing/0001628280-22-014063.md","text":"https://secwatch.observer/filing/0001628280-22-014063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022014063/0001628280-22-014063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022014063/cdxc-20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T17:55:54.266967+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}